SCOTTSDALE, Ariz., March 03, 2017 -- TPI Composites, Inc. (“TPI”) (Nasdaq:TPIC), the largest U.S.-based independent manufacturer of composite wind blades, today announced that its management team will attend the following investor conferences:
38th Annual Raymond James Institutional Investors Conference
March 6, 2017
Orlando, Florida
29th Annual ROTH Conference
March 14, 2017
Dana Point, California
About TPI Composites, Inc.
TPI Composites, Inc. is the largest U.S.-based independent manufacturer of composite wind blades for the wind energy market. TPI delivers high-quality, cost-effective composite solutions through long term relationships with leading wind turbine manufacturers. TPI is headquartered in Scottsdale, Arizona and operates factories throughout the U.S., Mexico, China and Turkey.
Investor Contact: [email protected] 480-315-8742


Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



